Rosuvastatin Counteracts Vessel Arterialisation and Sinusoid Capillarisation, Reduces Tumour Growth, and Prolongs Survival in Murine Hepatocellular Carcinoma
Figure 5
Rosuvastatin reduces the expression of active Notch4 in sinusoidal endothelial cells. (a) Representative images of CD31/Notch4 double immunostaining in untreated HCC livers at 16 weeks. We showed that Notch4 was expressed by CD31-positive endothelial cells lining the sinusoids (white arrowhead). (b) Representative images of Notch4 immunostaining in normal livers (N, ), untreated HCC, and in rosuvastatin-treated HCC livers (/group) at 16 weeks (white arrowhead). (c) Western blot analysis of active Notch4 in untreated HCC and in rosuvastatin-treated HCC livers (/group) at 16 weeks. The results were normalised to the β-actin levels and expressed as a percentage of Notch4 levels in untreated livers. Rosuvastatin decreased significantly the levels of active Notch4 in HCC livers. Data are mean ± SEM, .
